The Food and Drug Administration recently approved two novel thrombopoiesis-stimulating agents, Romiplostim (AMG-531, Nplate) and Eltrombopag (Promacta), for the treatment of adults with immune ...

Neonatal alloimmune thrombocytopenia is a rare but potentially life threatening condition in newborns. It can cause bleeding in the brain and long-term effects. Treatment usually involves a platelet ...

There is a lack of evidence-based guidelines for neonatal transfusion practices as seen by the diverse RBC transfusion practices among individuals and institutions. [3,5,27,28,29,30,31,32] The US ...

February 18, 2010 — Low doses of platelets given prophylactically led to a decreased number of platelets transfused per patient but an increased number of transfusions given, according to the results ...

Neonatal alloimmune thrombocytopenia (NAIT) is a disorder that affects pregnant people and their fetuses. It occurs when the birthing parent’s immune system produces antibodies that attack and destroy ...

The use of low-dose platelet transfusion in patients undergoing hematopoietic stem-cell transplantation with platelet counts less than 10,000/mm 3 did not significantly affect bleeding compared with ...

65.4% of hospitalized ITP inpatients did not have a bleeding episode or surgical procedure associated with their platelet transfusion. Platelet transfusions were not associated with improved clinical ...